Play­ing catch-up, Eli Lil­ly is hus­tling pos­i­tive PhI­II CGRP mi­graine da­ta to the FDA as late-stage ri­val­ry heats up

Eli Lil­ly is hus­tling up a bi­o­log­ics ap­pli­ca­tion for its close­ly-watched mi­graine drug gal­canezum­ab af­ter post­ing some re­mark­ably con­sis­tent and pos­i­tive late-stage da­ta from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER